Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Megestrol acetate
Drug ID BADD_D01372
Description 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Indications and Usage For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
Marketing Status Prescription; Discontinued
ATC Code G03AC05; G03DB02; L02AB01
DrugBank ID DB00351
KEGG ID D00952
MeSH ID D019290
PubChem ID 11683
TTD Drug ID Not Available
NDC Product Code 49884-289; 0121-4776; 72969-102; 17856-0907; 49884-290; 0009-5030; 60429-433; 77044-5047; 24979-041; 51927-1670; 49884-230; 68094-361; 63629-7631; 0904-3571; 63739-549; 46439-8722; 0555-0607; 0121-0945; 63629-2221; 64380-158; 49884-907; 71205-943; 55154-5776; 63629-2219; 66689-020; 81646-120; 50383-859; 63629-2220; 60432-126; 51991-313; 0555-0606; 43744-363; 63592-0109; 64380-159; 68094-250; 0904-7072
Synonyms Megestrol Acetate | Acetate, Megestrol | Lin-Megestrol | Lin Megestrol | LinMegestrol | Maygace | Megace | Megostat | Megestat | Megefren | Mestrel | Nu-Megestrol | Nu Megestrol | NuMegestrol | Borea | Apo-Megestrol | Apo Megestrol | ApoMegestrol
Chemical Information
Molecular Formula C24H32O4
CAS Registry Number 595-33-5
SMILES CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Glucose tolerance decreased13.02.02.004--Not Available
Glucose tolerance impaired05.06.02.001; 14.06.02.001--
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Herpes virus infection11.05.02.008--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.001972%
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.0020.003945%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Lung disorder22.02.07.001--Not Available
Malaise08.01.01.003--
Meningioma17.20.01.005; 16.30.01.0050.011834%Not Available
Menopausal symptoms21.02.02.002--Not Available
Metrorrhagia21.01.01.006--Not Available
Mood swings19.04.03.001--Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages